We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.40 | -6.67% | 19.60 | 20.00 | 20.50 | 21.50 | 20.25 | 21.00 | 572,429 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 7.13 | 18.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/3/2018 11:38 | Great ramp.. Will it help.. No.. Just like all the other mega ramps. | monkeywench1 | |
22/3/2018 11:37 | Excellent response from SoH, if investors can't see the scale of the opportunity here and how close we are to a tipping point (when the herd catch on) then IMHO they should stick to FTSE100 stocks. I'll continue to add on weakness. Some opportunity's are just to good to pass up on | trotterstrading | |
22/3/2018 11:33 | Great post Primal. | mouse20 | |
22/3/2018 10:58 | People are over reacting here when there is nothing wrong. I wrote to SOH, his response:"The current share price fluctuations are part of a trend we have seen a few times over the last 12 months where market makers and some traders selectively pick out a couple of areas to panic/concern investors to put download pressure on the price. History tells us that the price typically bounces back as the fundamentals on which the business has been built have not changes. These are:- 1. We are leading the field in the microbiome space, a market growing at 22.3% per year, and described by health experts as 'healthcare's most promising and lucrative frontier'. Our recent corporate visits to the US and across Europe added further reassurance to our belief that we have world leading technology which is exciting the interest of major corporates.2. The company has been built on four platforms: SkinBiotherapeutics (of which OptiBiotix owns 42%), OptiBiome (of which SlimBiome is one product), Optiscreen (where we have launched LP-LDL) and OptIBiotics (which includes our microbiome modulators). These diversify investor risk and create multiple opportunities across major markets. We believe we are unique in capturing such a wide breadth of opportunities in the microbiome space.3. In the last 3 years we have created new science, tested it in the laboratory, and then performed clinical studies, so we can be assured we have safe and effective products. Our products have won international awards and we have won awards for best science at major scientific events in both 2017 and 2018. This demonstrates the leading nature of both our science and products. We now have world leading key opinion leaders presenting our science for us which creates corporate interest. This is all part of building a strong and valuable business. 4. Our strategy has been clearly defined from the beginning: develop the science, strike joint development deals with global partners, prove the science in humans studies, and then strike deals with manufacturers, formulators, and distributors to commercialise the products. This is a track I have gone down many times and builds true value. 5. We have struck deals with major corporate partners such as Tata (x2) and DSM (the worlds largest ingredient supplier) to either manufacture product on a global scale or develop applications for themselves consistnet with our JV and JDA strategy. We are bound by confidentiality not to disclose the launch plans of these companies as we are the 'intel inside' and not the product owner.6. We are rapidly transitioning from a product development company to the commercial stage of the companies development. This started in Europe in May 2017 and USA in late September. Since then we have been developing a rich deal pipeline which we believe will build into significant revenues over time. We would hope to see each divisions building revenues of between £5-£10m in the forthcoming years giving valuations for each division of £50 to £100m. Most investors will have seen from the recent RNS's the gradual evolution from small privately owned pharma companies to larger >£100m revenue companies like Cereal Ingredients and Gallenicum. We will continue on this path as it reduces the dependency on one or two big deals but has to be negotiated carefully so as not to exclude the global opportunity.7. Given we are in a new space with new partners we believe providing revenue forecasts is high risk until we have completed our commercial transition. However, we have often provided guidance on likely deal contributions.8. Typical commercial deals should generate annual revenue in the £250,000 - £500,000 range for smaller privately owned companies with deals with companies with >£100m revenues typically worth £750k-£1.25m pa. We would also anticipate larger deals in the multi-million range with global corporates and large retailers.9. On AIM their is often a disconnect between the scale of opportunity and the share price which can often be artificially manipulated (higher or lower) with a number of trades. However, as outlined in my proactive interview investors should be able to see that we are building commercial momentum across all our platforms, starting with the smaller deals with pharma groups which are quicker to execute and building into larger deals with the likes of Cereal Ingredients, Gallenicum, and Fine Foods. We anticipate this trend will continue interspersed with a number of corporate and retail deals." | primal123 | |
22/3/2018 10:12 | IG and yesterday: I 'had' a small holding there (25k) and they were stopped out yesterday. Am I sorry - yes and no: glad to have this particular misery removed from my life, and will move back in when we really have turned the corner i.e. a demonstration of prospects of real significant income. Will I have to pay more? We shall see how low this goes. If I had got out when 80 and 70 weren't holding, then probably not. A lesson there for me that's for sure. Good luck all, and I genuinely mean that, am now concentrating on other stocks I hold. Best wishes - Mike | spike_1 | |
22/3/2018 09:39 | I phoned them up yesterday. Just general comments from the staff I spoke to. | pj 1 | |
22/3/2018 09:39 | I have a open short to take me to my core holding entry @ 53p. I explained my logic to a friend and that friend explained it to Soh. I know the dangers and accept those dangers. I don't expect to have my position open for very long, days in fact by the looks of the price action. | incanus | |
22/3/2018 09:31 | PJ can i ask how you would know in ref to the following. 'IG and Spreadex hadn't noticed any significant trades as of yesterday.' | pglancy | |
22/3/2018 09:26 | What shorts? | m4rtinu | |
22/3/2018 09:17 | Fully loaded, but drop to 50p will see me raiding the boys piggy bank | zebbo | |
22/3/2018 08:59 | The shorts have to close at some point and we know for a fact there's a few of those open! For me it could have made a few points but the risk reward for me on shorting this is crazy. Soh could surprise any day. S | shrewdmole | |
22/3/2018 08:58 | Lounge do touch need your bucket of tears emptied? | monkeywench1 | |
22/3/2018 08:46 | ramas 22 Mar '18 - 08:38 - 33451 of 33451 0 0 0 Feels like forward selling= ==================== Unsure ramas. IG and Spreadex hadn't noticed any significant trades as of yesterday. There are other providers though off course Pi's always fear price action pre Results, sometimes its an indicator, sometimes not. That support needs to hold. | pj 1 | |
22/3/2018 08:43 | Bulls still can't see it.They will.soon.. | vanduke | |
22/3/2018 08:38 | Feels like forward selling | ramas | |
22/3/2018 08:35 | Good ole Shrewdie,trouble is what happens to the share price when all these on this thread cannot "top up" anymore,'cause we don't seem to be getting any or very few new buyers. | scotty1 | |
22/3/2018 08:32 | The ramping has clearly been orchestrated. Unfortunately the Rampers are ineffectual... The market dictates the share price | monkeywench1 | |
22/3/2018 08:29 | Final capitulation? | malreid | |
22/3/2018 08:21 | Done my bit!! | shrewdmole | |
22/3/2018 08:17 | Yep, clearly orchestrated IMO. As I said yest.. where are the TR1's? There ain't none, and won't be none either | trotterstrading | |
22/3/2018 08:14 | Looks like another stormingly good day on the cards Persistent seller no buyers no news Perfectly bad storm!!! :( | judijudi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions